Back to top
more

Beauty Health (SKIN)

(Real Time Quote from BATS)

$3.15 USD

3.15
577,344

+0.09 (2.94%)

Updated Apr 26, 2024 12:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Compared to Estimates, The Beauty Health Company (SKIN) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for The Beauty Health Company (SKIN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 14.29% and 10.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Cencora (COR) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for The Beauty Health Company (SKIN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of 11.54% and 0.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Does The Beauty Health Company (SKIN) Have the Potential to Rally 122.94% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for The Beauty Health Company (SKIN) points to a 122.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Implied Volatility Surging for Beauty Health (SKIN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.

The Beauty Health Company (SKIN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 40% and 0.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Organon (OGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Beauty Health (SKIN) Stock Options

by Zacks Equity Research

Implied Volatility Surging for Beauty Health (SKIN) Stock OptionsInvestors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.

The Beauty Health Company (SKIN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

The Beauty Health Company (SKIN) delivered earnings and revenue surprises of -100% and 3.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

The Beauty Health Company (SKIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Beauty Health (SKIN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.

The Beauty Health Company (SKIN) Q4 Earnings Meet Estimates

by Zacks Equity Research

The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 0% and 3.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Beauty Health (SKIN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.

Elevance Health (ELV) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of 6.06% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?

by Zacks Equity Research

The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Organon (OGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of 7.76% and 5.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TRxADE (MEDS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

TRxADE (MEDS) delivered earnings and revenue surprises of -44.44% and 13.07%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Stock Jumps 5.6%: Will It Continue to Soar?

by Zacks Equity Research

The Beauty Health Company (SKIN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Wall Street Analysts See a 69% Upside in The Beauty Health Company (SKIN): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 69.3% upside potential for The Beauty Health Company (SKIN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.